Experimental drug BL-M02D1 takes first steps against tough cancers
NCT ID NCT05385692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing an experimental drug called BL-M02D1 in 22 people with advanced gastrointestinal or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tumors. The study is active but no longer recruiting new participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M02D1 (an experimental drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced gastrointestinal or other solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 22 participants, focused mainly on safety and dosing. The drug may not prove effective, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China